Pharmafile Logo
Pharmafocus logo
Advanced Search

Bayer

Showing 15 posts of 262 posts found.

FDA approves Bayer’s Stivarga

October 1, 2012
Research and Development, Sales and Marketing Bayer, FDA, KRAS, Roche, Stivarga, avastin

The FDA has approved Bayer HealthCare’s oncology pill Stivarga to treat patients with metastatic colorectal cancer (mCRC) whose disease has …

News

Acino plant opens to serve Bayer contraceptive patch needs

August 14, 2012
Manufacturing and Production Acino, Bayer, R&D, Swiss, contraceptive

Acino has officially opened its new manufacturing facility for transdermal patch products in Miesbach, Germany, which it says makes it …

News

Bayer raises guidance after strong sales

July 31, 2012
Sales and Marketing Bayer, Nexavar, Q2, Xarelto, Yasmin

The Bayer Group has raised its full-year guidance for 2012 following positive results in the second quarter. This is despite …

News
Bayer image

Bayer guilty of multiple Code breaches

July 30, 2012
Medical Communications, Sales and Marketing ABPI Code, Bayer, Xarelto, breach, clause

Bayer Healthcare has admitted to 12 breaches of the ABPI Code after one of its staff developed and distributed drug …

News
Xarelto image

NICE yes for Xarelto to treat blood clots

July 25, 2012
Sales and Marketing Bayer, DVT, NHS, NICE, Pradaxa, VTE, Xarelto

NICE is recommending Bayer’s Xarelto (rivaroxaban) for the treatment and prevention of deep vein thrombosis (DVT). The watchdog said in …

News
Xarelto image

Priority review for Xarelto’s new indications

July 10, 2012
Manufacturing and Production, Research and Development, Sales and Marketing Bayer, Boehringer, Eliquis, FDA, Janssen, Pradaxa, Xarelto

Xarelto is to be given a FDA fast-track review for a range of anti-blood clotting uses. Xarelto (rivaroxaban) gained its …

News
Xarelto image

FDA rejects licence extension for Xarelto

June 26, 2012
Sales and Marketing ACS, Bayer, FDA, J&J, JJ, Pradaxa, Xarelto

The FDA has set a Complete Response Letter to Bayer and J&J over its blood thinner Xarelto. The firms, which …

News
AstraZeneca image

AstraZeneca buys Ardea Biosciences

June 22, 2012
Research and Development, Sales and Marketing Abbott, Ardea Biosciences, AstraZeneca, Bayer, Humira, Takeda

AstraZeneca has completed its acquisition of US firm Ardea Biosciences in a $1.26 billion deal that it hopes will shore …

News
Social media

ABPI: we don’t have the answers for digital yet

June 14, 2012
Medical Communications, Sales and Marketing ABPI, Bayer, Deepak Khanna, Shire, digital, online

Pharma’s use of digital media is posing questions that can’t yet be answered, says the new ABPI president Deepak Khanna. …

News

Sanofi submits key MS pill for approval

June 12, 2012
Research and Development, Sales and Marketing Bayer, EMA, FDA, Genzyme, Lemtrada, MS, Sanofi

Sanofi has submitted its multiple sclerosis pill Lemtrada for regulatory reviews in the US and Europe. Lemtrada (alemtuzumab), originally developed …

News

UK Prix Galien shortlist announced

May 30, 2012
Business Services, Medical Communications, Research and Development, Sales and Marketing Bayer, Janssen, Xarelto, awards, prix galien

The UK award for the most innovative new drug has been moved a step closer with the release of a …

News
Xarelto picture

NICE recommends Xarelto for stroke prevention

May 23, 2012
Sales and Marketing Bayer, DVT, NICE, Pradaxa, Xarelto, anticoagulant

NICE is recommending Bayer’s anticoagulant pill Xarelto to help reduce the risk of stroke in certain patients.  The watchdog’s final …

News
Nexavar image

Torisel fails in head-to-head study with Nexavar

May 16, 2012
Research and Development, Sales and Marketing Bayer, Nexavar, Pfizer, Torisel, inlyta, rcc

Pfizer’s kidney cancer drug Torisel has failed to best Bayer’s Nexavar in a head-to-head trial.  The Phase III study was …

News

Algeta to co-promote Alpharadin in US

April 12, 2012
Sales and Marketing Algeta, Bayer, prostate cancer

Algeta has exercised its option to co-promote Alpharadin for the treatment of cancer patients with bone metastases in the United …

News
Bayer image

Bayer cancer drug meets Phase III goal

April 3, 2012
Research and Development, Sales and Marketing Bayer, Cancer, Glivec, Novartis, phase III, regorafenib

Bayer’s stomach cancer pill regorafenib has significantly improved progression free survival in late-stage patients. Results from the Phase III trial …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025